After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...